In addition, a phase 1 trial of an anti-CD47 antibody in AML and MDS showed objective responses in 64% of patients with AML and 92% of patients with MDS when the anti-CD47 antibody was given in combination with azacytidine; a CR was achieved in 55% and 50% of patients, respectively (NCT03248479) [187]. The gene discussed is CD47; the disease is acute myeloid leukemia.